Table 1.
Clinical characteristics of the study cohorts
| Characteristic | |
|---|---|
| Localized prostate cancer cohort | |
| Patients, n | 458 |
| Age at diagnosis | |
| Median, years (IQR) | 66 (61–70) |
| PSA at diagnosis | |
| Median, ng/mL (IQR) | 11.1 (7.1–17.5) |
| Pathologic Gleason score, n (%) | |
| < 7 | 160 (35.3) |
| 7 | 232 (51.2) |
| > 7 | 61 (13.5) |
| Pathologic stage, n (%) | |
| T1/T2 | 303 (67.2) |
| T3/T4/N1 | 148 (32.8) |
| M1 | 0 (0.0) |
| Disease progression | |
| No | 274 (59.8) |
| Yes | 184 (40.2) |
| Advanced prostate cancer cohort | |
| Patients, n | 324 |
| Age at diagnosis | |
| Median, years (IQR) | 72 (66–78) |
| PSA at ADT initiation | |
| Median, ng/mL (IQR) | 32.6 (9.4–123.4) |
| Biopsy Gleason score at diagnosis, n (%) | |
| < 7 | 70 (22.2) |
| 7 | 131 (41.5) |
| > 7 | 115 (36.4) |
| Clinical stage at diagnosis, n (%) | |
| T1/T2 | 92 (28.6) |
| T3/T4/N1 | 103 (32.0) |
| M1 | 127 (39.4) |
| PSA nadir | |
| Median, ng/mL (IQR) | 0.12 (0.01–1.08) |
| Treatment modality | |
| ADT as primary treatment | 138 (42.7) |
| ADT for post RP PSA failure | 39 (12.1) |
| ADT for post RT PSA failure | 6 (1.9) |
| Neoadjuvant/adjuvant ADT with RT | 101 (31.3) |
| Others | 39 (12.1) |
| Disease progression | |
| No | 28 (8.6) |
| Yes | 296 (91.4) |
IQR, interquartile range; PSA, prostate-specific antigen; ADT, androgen-deprivation therapy; RP, radical prostatectomy; RT, radiation therapy